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Abstract
The human ovarian surface epithelium (HOSE) is a
common site of gynaecological disease including endo-
metriosis and ovarian cancer, probably due to serial
injury-repair events associated with successive ovulations.
To comprehend the importance of steroid signalling in the
regulation of the HOSE, we used a custom microarray to
catalogue the expression of over 250 genes involved in the
synthesis and reception of steroid hormones, sterols and
retinoids. The array included a subset of non-steroidogenic
genes commonly involved in pro-/anti-inflammatory sig-
nalling. HOSE cells donated by five patients undergoing
surgery for non-malignant gynaecological conditions were
cultured for 48 h in the presence and absence of 500 pg/
ml interleukin-1 (IL-1). Total RNA was reverse-
transcribed into biotin-labelled cDNA, which was hybrid-
ised to the array and visualised by gold-particle resonance
light scattering and charge-coupled device (CCD) camera
detection. Results for selected genes were verified by
quantitative reverse-transcription PCR. In five out of five
cases, untreated HOSE cells expressed genes encoding
enzymes required for de novo biosynthesis of cholesterol
from acetate and subsequent formation of C21-pregnane
and C19-androstane steroids. Consistent with the inability
of HOSE cells to synthesise glucocorticoids, oestrogens
or 5-reduced androgens de novo, CYP21, CYP19 and
5-reductase were not detected. The only steroidogenic
gene significantly up-regulated by IL-1 was 11-
hydroxysteroid dehydrogenase type 1 (11HSD1). Other
cytokine-induced genes were IL-6, IL-8, nuclear factor B
(NFB) inhibitor , metallothionein-IIA and lysyl oxidase:
inflammation-associated genes that respond to glucocorti-
coids. The only steroidogenic gene significantly suppressed
by IL-1 was 3HSD1. Other genes suppressed by IL-1
were aldehyde dehydrogenase (ALDH) 1, ALDH 10,
gonadotrophin hormone-releasing hormone receptor, per-
oxisome proliferation-activated receptor-binding protein
(PPAR-bp) and nuclear receptor subfamily 2 group F
member 2. These results define a steroidogenic phenotype
of cultured HOSE cells and provide a limited expression
profile for genes with associated signalling functions.
IL-1 co-ordinately induces 11HSD1 and a panel of
glucocorticoid-regulated, inflammation-associated genes
in HOSE cells, providing further evidence that cortisol
generated by 11HSD1 could participate in the local
resolution of inflammation associated with ovulation.
Journal of Endocrinology (2004) 183, 19–28
Introduction
The steroid-secretory function of the ovaries is well
recognised but the capacity of the human ovarian surface
epithelium (HOSE) to synthesise, metabolise and respond
to steroids remains obscure. The probable importance of
steroid signalling in the HOSE relates to the tendency of
this cellular layer to undergo neoplastic transformation and
produce fatal tumours. Ovarian cancers represent approxi-
mately 4% of all gynaecological cancers and are the fifth
highest cause of death from cancer among women. Over
90% of ovarian cancers in women are believed to originate
in the HOSE. Many such cancers are steroid responsive
and one of the major negative-risk factors is anovulation
associated with steroidal oral contraceptive usage. HOSE
cells are believed to be steroid responsive on the basis that
exposure to ovarian steroids in vitro aﬀects HOSE cell
proliferation (Karlan et al. 1995) and that they express
nuclear hormone receptors, including oestrogen receptor
(ER; Hiller et al. 1998, Lau et al. 1999, Li et al. 2003),
androgen receptor (AR; Lau et al. 1999, Edmondson et al.
2002) and progesterone receptor (PR; Karlan et al. 1995,
Lau et al. 1999, Li et al. 2003), which presumably mediate
these eﬀects. Involvement of HOSE cells in steroid
biosynthesis is less certain. However, definitive evidence
for steroid metabolism comes from the recent discovery
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that cultured HOSE cells express the glucocorticoid-
metabolising enzyme 11-hydroxysteroid dehydrogenase
type 1 (11HSD1), which is up-regulated by exposure
to interleukin-1 (IL-1) (Yong et al. 2002, Rae et al.
2004). Pro-inflammatory cytokines such as IL-1 are
increasingly produced by follicular cells at the time of
ovulation, therefore up-regulation of 11HSD1 could be a
mechanism for increasing local metabolism of substrate
cortisone to cortisol and promoting anti-inflammatory
glucocorticoid action at the ovarian surface (Hillier &
Tetsuka 1998).
To define the steroidogenic signature of the HOSE we
developed a custom gene microarray probing the enzymes
that catalyse the complete steroidogenic pathway, from
acetate through cholesterol to the principal hormonal
steroids and their metabolites. The gene-set also contains
nuclear receptors of known and unknown functions
and a limited selection of genes encoding pro-/anti-
inflammatory mediators. Here we apply this microarray to
analyse RNA from primary HOSE cell cultures, with and
without prior exposure of cells to IL-1. The results define
a steroidogenic phenotype of normal HOSE cells and
identify a panel of associated HOSE genes with likely roles
in normal and abnormal ovarian function. Several such
genes are glucocorticoid responsive and are likely to
be involved in the injury-repair process associated with
ovulation.
Materials and Methods
Patients
HOSE cells were obtained (with informed consent after
local ethics committee approval) from normal ovaries of
eight premenopausal women undergoing surgery for non-
malignant gynaecological conditions. Cells were collected
at laparotomy by gentle scraping of the ovarian surface
with a sterile wooden spatula, which was then rinsed into
sterile, pre-warmed, culture medium (see below). Cells
were collected as near as practicable to the beginning of
the surgical procedure to avoid any contamination with
blood cells. Collections were then examined by phase-
contrast microscopy to verify that a representative biopsy
of the HOSE had been recovered.
Production of HOSE cell monolayers
All cultures were produced and handled in an identical
manner, using reagents made from a common stock. The
tissue culture reagents were obtained from Gibco and
Sigma. HOSE scrapings were cultured in donor calf
serum-precoated flasks (75 cm2; Corning Inc, Glass
Works, Corning, NY, USA). Culture medium (HOSE 1)
consisted of Medium199:MCDB105 (1:1 v/v) supple-
mented with fetal calf serum (15% v/v), streptomycin
(50 µg/ml), penicillin (50 IU/ml) and -glutamine
(2 mM) (Yong et al. 2002). Cells were incubated at 37 C
in a humidified incubator under an atmosphere of 95%
air–5% CO2 for 21 days, with medium renewed every 7
days. HOSE cell monolayers were routinely examined by
phase-contrast microscopy for contaminating fibroblasts.
Cell purity was checked in selected cases by immuno-
cytochemical staining for cytokeratin 5, 6, 8 and 17
(Auersperg et al. 2001) using a commercially available
monoclonal anti-human cytokeratin antibody (Dako, Ely,
Cambridgeshire, UK), which confirmed that the mono-
layers comprised pure epithelial cells (data not shown).
Experimental treatment of cultured HOSE cells
Each set of experiments was applied identically to cells
donated by five diﬀerent patients. HOSE cell monolayers
(21 days old) were dispersed by treatment with trypsin-
EDTA in Hanks’ balanced salt solution (0·05% w/v
trypsin, 0·5 mM EDTA, Invitrogen) for exactly 5 min at
37 C. Cells were collected by centrifugation for 5 min at
800 g, and the pellet was washed once and re-susupended
in fresh HOSE 1 medium. Cell counts were done with a
haemocytometer using trypan blue (Sigma) dye-exclusion
to determine viability (75–90%). The cell suspension was
adjusted to a concentration of 100 000 cells/ml with
HOSE 1 medium and 15 ml portions dispersed into fresh
75 cm2 culture flasks, which were incubated for 24 h at
37 C to allow cell attachment. The medium was then
replaced with serum-depleted medium (HOSE 2) con-
taining 0·01% BSA (w/v) and incubation continued for a
further 24 h. Spent medium was then replaced with
fresh HOSE 2 containing no addition (control) or
500 pg/ml recombinant human IL-1 (R&D Systems
Europe Ltd, Abingdon, Oxon, UK), with incubation for
48 h at 37 C. These conditions have previously been
shown to be optimal for inducing 11HSD enzymatic
activity in cultured HOSE cells (Yong et al. 2002,
Rae et al. 2004). Total RNA was then extracted from
the cell monolayers as described below. Additional
experiments to establish the eﬀects of cortisol on IL-1-
induced lysyl oxidase (LOX) gene expression were per-
formed as previously described (Rae et al. 2004), using
primary HOSE cell cultures donated by a further three
patients.
RNA extraction and quality analysis
RNA was extracted using RNeasy minispin columns
(Qiagen) as per manufacturer’s protocols, in combination
with on-column DNase-I treatment (Qiagen). Aliquots
(1 µl) of purified RNA were removed for quantifica-
tion and quality assessment of total RNA using the
Agilent 2100 Bioanalyser system in combination with
RNA6000nano chips (Agilent Technologies, Cheshire,
UK). Only RNA that displayed intact 18S and 28S peaks
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was reverse transcribed (RT) to cDNA for real-time PCR
analysis. This quality-control step was included for each
experimental run to avoid generation of false-negative
results due to RNA degradation before and during extrac-
tion steps, and also as a quantification method to ensure
equal amounts of RNA were transcribed in each RT
reaction.
EUROSTERONE microarray fabrication
The gene sets used on the microarray were chosen by the
European Commission funded EUROSTERONE con-
sortium (Hillier 2003), comprising 256 genes involved in
steroid signalling, including enzymes of the major bio-
chemical pathways of cholesterol and steroid hormone
biosynthesis, nuclear hormone receptors and a subset of
associated genes implicated in pro-/anti-inflammatory
signalling. Fifty-mer oligonucleotides specific for each
gene were selected in-house and synthesised by MWG
(Milton Keynes, UK). Oligonucleotides were dissolved in
75 mM sodium-phosphate buﬀer containing 0·005%
(w/v) SDS. Plates of oligonucleotide solutions were pre-
pared using a Roboamp4200 (MWG) and spotted in
triplicate on to Corning GAPS II slides (25 27 mm
bar-coded, lot. 34802000B, Corning, Netherlands) using a
MG2 array spotter (Biorobotics, Cambridgeshire, UK) in
conjunction with 200 µm solid pins, producing a spot
diameter of 310–330 µm, under temperature and humid-
ity conditions of 16–18 C and 35–45% respectively.
After spotting was complete and slides had dried, oligo-
nucleotide spots were covalently linked to the aminosilane
slide coating by exposure to u.v. light (250 mJ) (GS
Genelinker UV chamber, BioRad). The arrays were
stored desiccated at room temperature for use within 2
weeks of preparation to avoid any potential decline in
sensitivity.
Preparation of labelled cDNA and hybridisation
Biotin-d-11-UTP (Roche) was incorporated into cDNA
during reverse transciption using a Labelstar kit as per
manufacturer’s instructions (Qiagen); in each case using
exactly 6 µg (as measured by an Agilent Bioanalyser, and
confirmed by spectrophotometry) Dnase-treated RNA.
The protocol used in the Labelstar kit can be used with
0·5–50 µg RNA template. An advantage of this method is
the endogenous exonuclease activity of the reverse tran-
scriptase enzyme preparation, which avoids unnecessary
lysis of RNA template by harsh reagent conditions. cDNA
was purified from reaction mixtures by silica-gel binding
columns (Qiagen). Hybridisation of exactly 50% of the
cDNA produced (equivalent to 3 µg RNA template) was
carried out for 18 h at 42 C in a humidified hybridisation
oven using reagents from a Qiagen HiLight single-colour
(gold particles) array detection hybridisation kit. The
hybridisation chambers used were single-slide, rubber-
sealed units (Camlab, Cambridge, UK). Post-hybridisation
washes and detection by addition of anti-biotin serum
labelled with colloidal gold was performed as described by
the manufacturer’s (Qiagen) protocols, except that solution
removal was done by centrifugation and the volume of
each kit component was adjusted for use with the smaller
print area of the array used in this study. In pilot studies,
we found that these methods of hybridisation and subse-
quent detection by gold-particle resonance-light scattering
and charge-coupled device (CCD) camera detection
were>10-fold more sensitive than conventional Cye-3/5
labelling and detection strategies as regards signal intensity
and amount of template RNA required. We ascertained
using the resonance-light scattering system that negligible
diﬀerences in results occurred using between 1 and 5 µg
RNA-templated cDNA, and greater amounts of RNA
template were found to be deleterious to array detection.
A separate chip was used to analyse each sample (i.e.
control and treated samples from each patient were run on
separate chips), thus avoiding the need for dye/metal
particle-swap experiments.
Scanning and analysis
Each array was scanned eight times at increasing CCD
camera exposure times (there is no photo-bleaching eﬀect
with this type of detection). Bitmap scan files were then
quantified using Quantarray (Perkin-Elmer, Chalfont,
Bucks, UK), using fixed-circle detection parameters, and
the resulting comma separated value (CSV) format data
exported to Microsoft Excel for manipulation and analysis.
Scatter-plots of each scanner setting were created and used
to identify which CCD setting gave the optimal dataset for
each array, as previously described (Forster et al. 2003).
Optimal scanner data for each array were then normalised
to the mean 75th percentile of total array signal (global
normalisation, as previously described (Forster et al. 2003).
As a data-quality filter, the sensitivity threshold for each
array was taken as the 80th percentile of 15 negative-
control genes. Values below this number were removed
from the dataset for that particular array. In rare cases
where genes were either newly induced or completely
suppressed by treatment, sub-sensitivity threshold values
were analysed to permit statistical analysis of treatment
eﬀects. Data were logarithmically transformed to base 2,
then further analysed with a t-test for dependent samples
(paired, two-way t-test) on a per-gene basis, utilising the
statistical dependence between the treated and untreated
samples per patient to best eﬀect. Statistical sample size
was limited by patient numbers, therefore consistent with
our hypothesis-driven approach, analysis was limited to an
‘interest-filter’ approach whereby genes were selected on
their significance levels (cut-oﬀ for statistical significance
was set at alpha=0·05). Permutation testing was used to
confirm or refute these analyses, and a subset of
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genes significantly modulated by treatment were further
validated by real-time PCR analysis (below).
Real-time PCR analysis
DNase-treated (Qiagen) RNA (200 ng) was reverse tran-
scribed (RT; random hexamer kit; Applied Biosystems,
Warrington, UK) and 2 µl of the resultant RT-mix
analysed. cDNA was analysed in a 25 µl final assay volume
containing 300 nM primers and 200 nM TaqMan hybridi-
sation probe (Biosource UK Ltd, Essex, UK). Primers and
probes were designed using Primer-Express software
(Perkin-Elmer, Boston, MA, USA) and validated prior to
use (11HSD1 primers and probe; Yong et al. 2002), or
were purchased pre-validated from Applied Biosystems
(Assay-on-Demand systems). Target mRNA was quanti-
fied in relation to 18S ribosomal RNA abundance in
each sample. Negative controls consisted of RT-negative
(RNA template with no reverse transcriptase enzyme),
and RT-H2O (water in place of RNA template) samples
generated at the time of reverse transcription of samples,
plus a TaqMan-reaction negative control where cDNA
was replaced with water. In the case of the experiments
examining the eﬀects of glucocorticoids on IL1-
modulated genes (LOX), this was performed as previously
described for a range of other genes in HOSE cells (Rae
et al. 2004), using a 48 h treatment-incubation time in all
cases. Data were logarithmically transformed to base 10
and then analysed by ANOVA with Student’s t-test to
determine specific treatment eﬀects.
Results
Untreated HOSE cells from all five patients expressed
genes encoding many of the enzymes involved in classic
pathways of steroid biosynthesis metabolism and action.
The full normalised signature dataset is provided as a
supplementary table to the online version of Journal of
Endocrinology (see http://joe.endocrinology-journals.
org/content/vol183/issue1/). In addition, original data as
well as selected data not shown in the manuscript are
available (accession no. GXE-00021), in the MIAME
compliant GTI expression pathway database, GPXdb-
(http://www.gti.ed.ac.uk).
Steroid biosynthesis
All the enzymes required for de novo formation of C21-
pregnane and C19-androstane steroids from acetate via
cholesterol were significantly detected. However, CYP21
and CYP19 were not expressed at levels above the
sensitivity threshold of the array, suggesting that HOSE
cells are unlikely to be able to undertake de novo syn-
thesis of biologically active glucocorticoids or oestrogens
(Fig. 1).
Figure 1 Steroidogenic signature of cultured HOSE cells. Schematic summary of potential
for de novo steroid synthesis and metabolism under basal conditions of culture, based
upon EUROSTERONE custom microarray analysis.
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Steroid-metabolising enzymes
Relatively abundant expression of many key steroid-
metabolising enzymes was apparent, including members of
the steroid dehydrogenase/reductase (SDR) gene family
responsible for inter-conversion of active and inert con-
geners of hormonal steroids: 3HSD1, 11HSD1 and
17HSD types 1, 2, 4 and 7. The testis-specific 17HSD
isoform, 17HSD3, was not expressed. Steroid 5-
reductase types 1 and 2 were also not expressed above
sensitivity threshold levels (although steroid 5-reductase
was), implying an inability of HOSE cells to produce
5-reduced androgens. Enzymes (CYP11B1 and
CYP11B2) required for the metabolism of glucocorticoids
to the mineralocorticoid aldosterone were present, as were
those involved in the formation and hydrolysis of conju-
gated sex steroids. These last included steroid sulphatase,
which converts oestrone-sulphate into oestrone. Oestro-
gen sulphotransferase which catalyses the reverse reaction,
was not expressed.
Nuclear receptors
Nuclear receptors for oestrogens (ER and ER), proges-
terone (PR), glucocorticoids (GR) and androgens (AR)
were all present. Other nuclear receptor and related genes
expressed by HOSE cells included: retinoic acid receptor
(RAR), RAR4 and RAR; thyroid hormone recep-
tors (TR2); peroxisome-proliferation-activated receptors
(PPAR), PPAR2 and related proteins, PPAR co-
activator 1 and PPAR-binding protein (transcription
coactivator PBP); heat-shock protein 90 (Hsp90) and a
range of orphan nuclear receptors.
Responsiveness to IL-1
Of the core genes on the microarray directly involved in
steroid signalling, only one (11HSD1) was stimulated and
another (3HSD1) inhibited by treatment with IL-1. A
total of 12 genes were significantly aﬀected by treatment
with IL-1 (Fig. 2). The aﬀected genes are listed in
Tables 1 and 2, showing positive and negative responders
respectively.
Verification by PCR
RT-PCR was performed to verify that the observed
changes in gene expression level, determined by micro-
array, accurately reflect transcript induction. Using the
Figure 2 Regression plot of global effects of IL-1 treatment (500 pg/ml, 48 h duration)
on primary cultures derived from five separate women (mean of five experiments). Upper
line indicates 2-fold up-regulation, lower line indicates 2-fold down-regulation, middle line
indicates no regulation by IL-1. Open circles represent genes whose expression profiles
were found to be significantly different over the n=5 population between untreated and
IL-1-treated cultures.
Table 1 Genes in cultured HOSE cells up-regulated by treatment
with IL-1, based upon EUROSTERONE custom microarray
analysis (mean fold changeS.E.M.)
Name Fold change P value
Genebank no.
XM031289 Interleukin-8 +3·720·46 <0·01
M14584 Interleukin-6 +4·931·20 <0·01
J00271 Metallothionein-IIA +2·490·59 <0·05
M69043 NFB inhibitor  +2·430·55 <0·05
AH006349 11HSD type 1 +1·830·12 0·01
S78694 Lysyl oxidase +2·110·43 <0·05
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same RNA preparation used for microarray analysis,
gene-specific PCR was performed on a selection (n=7) of
the genes modulated by IL-1.
This analysis confirmed the reliability of the microarray
data: all the genes tested showed the predicted shifts
in expression, and to a generally comparable degree
(Table 3).
Responsiveness to glucocorticoid
Non-steroidogenic genes induced by IL-1 were deemed
by definition to be ‘inflammatory’ and therefore were
predicted to be responsive to cortisol, the metabolic
product of 11HSD1. This hypothesis was tested on LOX
(an enzyme crucial to the deposition of mature collagen
and elastin), showing reversal of IL-1-stimulated LOX
mRNA by cortisol in HOSE cell cultures from three out
of three patients (Fig. 3).
Discussion
We demonstrate that cultured HOSE cells express all the
genes required to synthesise de novo steroids in the C21-
pregnane and C19-androstane series. They also express
steroid dehydrogenase, hydroxylase and conjugation/
deconjugation enzymes that endow the capacity to
reversibly activate or inactivate multiple steroidal sub-
strates. Critically, however, they lack detectable CYP19,
necessary for androgen aromatisation to oestrogen, and
CYP21, required for C-21 hydroxylation and production
of glucocorticoids.
This custom microarray analysis powerfully reinforces
previous reports that human (Rembiszewska & Brynczak
1985) and sheep (Murdoch et al. 1999) OSE cells have
limited steroid biosynthetic potential. It was not feasible to
verify this conclusion exhaustively at the metabolic level.
However, consistent with absence of CYP19 and presence
of 11HSD1 gene expression defined by the microarray,
we confirmed absence of measurable aromatase enzyme
activity (data not shown) but presence of 11-oxoreductase
(Yong et al. 2002) in cultured HOSE cells. This, com-
bined with the verification of selected genes by quantitat-
ive RT-PCR (Table 3), provides a strong measure of
confidence in the validity of the present microarray
dataset.
Exposure of HOSE cells to IL-1, as a surrogate
inflammatory stimulus, was expected to cause pronounced
changes in the steroidogenic expression profile of HOSE
cells. In agreement with our previous finding (Yong et al.
2002), 11HSD1 was stimulated by the cytokine. How-
ever, only one other steroidogenic gene was aﬀected:
3HSD1, which was suppressed. 3HSD1 plays a critical
role in steroid interconversion through catalysing the
formation of ‘mature’ 4-3-oxo-C21 and -C19 products
(progesterone, androstenedione) from immediate 5-3-
hydroxy precursors (pregnenolone, dehydroepiandroster-
one). Thus, at least during exposure to inflammation such
Table 2 Genes in cultured HOSE cells down-regulated by treatment with IL-1, based upon
EUROSTERONE custom microarray analysis (mean fold changeS.E.M.)
Name Fold change P value
Genebank no.
Y13467 PPARbp 1·510·06 0·01
AH005567 GnRH receptor 1·290·06 <0·05
AF003341 Aldehyde dehydrogenase 1 soluble 2·600·09 <0·05
S45679 3HSD1 2·170·12 <0·05
M64497 Nuclear receptor subfamily 2
group F member 2 (COUP-TF II)
1·360·08 <0·05
I47162 Aldehyde dehydrogenase 10 1·240·06 <0·05
Table 3 Subset of IL-1-regulated genes randomly selected and validated by quantitative
real-time PCR on the same samples subjected to microarray analysis (mean fold
changeS.E.M.)
Name Fold change P value
Genebank no.
M14584 Interleukin-6 +20·9310·66 <0·05
M69043 NFB inhibitor  +4·610·98 <0·05
AH006349 11HSD type 1 +12·943·89 <0·01
S78694 Lysyl oxidase +3·180·31 <0·01
Y13467 PPARbp 1·350·13 <0·05
AF003341 Aldehyde dehydrogenase 1 soluble 4·740·53 <0·01
S45679 3HSD1 4·280·37 <0·01
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as encountered during ovulation, the HOSE is likely to
function less as a de novo steroid hormone-producing tissue
than one of steroid transformation.
11HSD1 and 3HSD1 are members of the SDR gene
family, which encode enzymes that reversibly metabolise
lipid-signalling molecules such as steroids, retinoids and
prostaglandins (Oppermann 2001). Other SDR probes in
the microarray included ALDH10 and ALDH1 soluble,
both of which were expressed in HOSE cells and down-
regulated by treatment with IL-1. ALDH isoforms con-
stitute a large family of enzymes with the general reaction
of catalysis of oxidation of long-chain aliphatic aldehydes
to fatty acids, but may also act on steroidal substrates. For
instance, yeast SDRs FOX2 and AYR1 are active on
long- and short-chain (3R)-hydroxyacyl-CoA substrates
(Qin et al. 1999) and 1-acyl dihydroxyacetone phosphate
(Athenstaedt & Daum 2000) respectively, but display
surprisingly robust 17HSD activity on dehydroepian-
drosterone (DHEA)/androstenediol (Vico et al. 2002);
some long-chain fatty acyl substrates may fold to adopt a
steroid-like configuration on enzyme binding. The func-
tion of ALDHs also include reversible oxidation/reduction
of retinol and retinal (Duester 2000), providing a
mechanism for gating access of these ligands to RAR’s.
We found RAR, RAR4 and RAR genes expressed
in HOSE cells, underscoring the likelihood that ligand-
activated RAR signalling is important to their develop-
ment and survival in vivo (Um et al. 2001).
The presence of GR supports our central hypothesis
that glucocorticoid fulfils anti-inflammatory signalling
functions in the HOSE (Rae et al. 2004). This last study
used quantitative RT-PCR to distinguish weak up-
regulation of GR mRNA by IL-1, which was not
resolved by the microarray analysis used here, presumably
due to its relative insensitivity.
The expression of PPAR, PPAR 2, PPAR co-
activator 1 and PPAR-binding protein, and down-
regulation of PPARbp by IL-1, is of special interest in
view of the inferred overlaps between glucocorticoid and
PPAR signalling (e.g. Lemberger et al. 1996, Johnson et al.
1999). However, many studies addressing PPAR function
have depended on the thiazolidinedione (TZD) group of
drugs such as eﬀectors; this area may need to be reinter-
preted in the light of a recent suggestion that TZDs
primarily target a mitochondrial protein (Colca et al.
2004). PPARbp (also PBP) was identified as a coactivator
for PPAR but also binds to PPAR, RAR, RXR and
TP1 (Zhu et al. 1997), and a role in thyroid hormone
signalling has been emphasised (Misra et al. 2002). In
addition, over-expression of PPARbp has been reported in
one-quarter of breast cancers examined, indicating a role
in mammary epithelial diﬀerentiation and cancer develop-
ment (Zhu et al. 1999) that may translate to the ovary.
Suppression of PPARbp by IL-1 is novel, and possibly
mediated via nuclear factor B (NFB), since there is a
putative binding site for NFB on the PPARbp gene
(Zhu et al. 1999).
The presence of ER and , AR and PR confirms
HOSE cells as sex-steroid targets, underscored by the
detection of Hsp90, a molecular chaperone with an
established function in the stabilisation of non-liganded
nuclear receptors (Cadepond et al. 1991). The relative
importance of ER and ER in mediating cytoprolifera-
tive and other eﬀects of oestrogen on HOSE cells is
unknown but both are expressed (Hillier et al. 1998, Li
et al. 2003). Notably, although steroid sulphatase was ex-
pressed, oestrone sulphotransferase was not. Thus HOSE
cells may be exposed to locally enhanced levels of oestro-
gen by activation from oestrone sulphate, which circulates
as the most abundant oestrogen in blood (Loriaux et al.
1971). Onward metabolism of oestrone to oestradiol is also
predicted by the pattern of 17HSD isoforms expressed. In
support of this suggestion, in studies examining the role of
oestrogens in normal OSE and malignant OSE cells,
oestrone was found to be as eﬀective as oestradiol in
promoting cell proliferation (Syed et al. 2001); data pre-
sented here may explain this finding. The presence of
AR in HOSE is in agreement with the pro-proliferative/
anti-apoptotic eﬀect of androgen on a virally transformed
HOSE cell line reported by Edmondson et al. (2002). The
presence of PR agrees with the anti-proliferative (Karlan
et al. 1995, Murdoch & Van Kirk 2002) and anti-
inflammatory (Rae et al. 2004) eﬀects of progesterone that
others have described. Additionally, we note expression of
the membrane-bound progesterone receptor, providing a
potential alternative route of progesterone action on these
cells.
Other nuclear receptors expressed in HOSE cells
include oestrogen-related receptors (ERR) and ERR,
which share a DNA-binding domain with ER but are
not activated by classical oestrogens. Their function in
Figure 3 Glucocorticoid-suppression of IL-1-induced LOX
mRNA expression in cultured HOSE cells. Real-time PCR was used
to determine gene expression changes due to IL-1 and cortisol in
primary HOSE cultures derived from three women. IL-1
significantly increased expression of LOX mRNA (P<0·05). Cortisol
alone had no effects; however, at all doses tested, it prevented the
stimulatory effects of IL-1 (P<0·05 as compared with IL-1
alone). *Significant difference, P<0·05.
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HOSE cells is yet to be defined but, at least for ERR, a
role in fatty acid metabolism is possible (Sladek et al. 1997).
HOSE cells also express TR2 and TR. To our knowl-
edge, no published reports exist of thyroid hormone action
on HOSE cells. However, epidemiological links between
development of ovarian cancer, inflammation of the
ovarian surface and hyperthyroidism have been previously
established (Ness et al. 2000). In rats, direct action of
thyroid hormones on the ovary has been discussed (Horii
et al. 1992); studies in women have pointed to thyroid
insuﬃciency as a possible cause of infertility (Gerhard et al.
1991, Raber et al. 2003). Further studies to elucidate the
signalling function of thyroid hormone in normal and
diseased HOSE cells are therefore urgently required.
Two genes in the array other than 3HSD1, ALD1
soluble, ALD 10 and PPARbp were significantly
down-regulated by IL-1 treatment. Expression of
gonadotrophin-releasing hormone receptor (GnRH-R)
has previously been demonstrated in HOSE cells, for
which GnRH is anti-proliferative in vitro (Kang et al.
2000). The functional significance of its suppression by
IL-1 remains unknown. The orphan steroid/retinoid
receptor nuclear receptor subfamily 2 group F member 2
(also known as chicken ovalbumin upstream promoter
transcription factor II-COUP TF II) was also down-
regulated by treatment with IL-1. We are unaware of
any previous report of this gene being expressed in the
ovary. Its spatiotemporal expression pattern during mouse
development suggests involvement in angiogenesis
(Pereira et al. 1999). Such a role could be relevant to
post-ovulatory tissue remodelling in the ovary. Impor-
tantly, it has been suggested that this gene may be a
potential therapeutic target in disease conditions such as
cancer where aberrant angiogenesis is a hallmark of disease
progression (Pereira et al. 1999).
Treatment with IL-1 stimulated the expression of
five non-steroidogenic genes in the array, other than
11HSD1: metallothionein-IIA (MT-IIA), previously
implicated in protection against the oxidative stress gen-
erated by the inflammation associated with ovulation
(Espey et al. 2003); IL-6 and IL-8, established components
of the ovulation-associated inflammatory cascade; LOX,
responsible for the final catalysis of collagen formation and
hence ECM deposition (Harlow et al. 2003); and NF
inhibitor , expression of which is associated as a down-
stream consequence of NF signalling, which is in turn
associated with inflammatory signalling. It has not escaped
our attention that all these IL-1-responsive genes are
potentially regulated by glucocorticoids in HOSE cells.
Thus, cortisol dose-dependently enhances IL-1-
stimulated 11HSD1 expression in HOSE cells (Rae et al.
2004); tumour-necrosis factor- (TNF)-induced expres-
sion of IL-8 and Il-6 mRNA in human fibroblasts
is suppressed by dexamethasone (Tobler et al. 1992);
MT-IIA possesses a GR response element and is inducible
by glucocorticoids (Karin et al. 1984); LOX enzyme
activity in rat skin is inhibited by glucocorticoids (Counts
et al. 1986), and as shown here, cortisol suppresses IL-1-
induced LOX mRNA expression in HOSE cells. This
leads us to suggest that induction by IL-1 of 11HSD1,
augmented by cortisol, might serve to generate the
glucocorticoid required to induce/repress anti-/pro-
inflammatory gene responses in vivo (Rae et al. 2004).
Moreover, through augmenting IL-1-stimulated
11HSD1 activity, cortisol would sustain its own regen-
eration and thereby amplify GR-mediated anti-
inflammatory signalling in the postovulatory HOSE (Rae
et al. 2004). However, although cortisone is the classic
11HSD1 substrate, we cannot rule out the possibility that
other substrates for this enzyme are present in HOSE cells.
Caveats to this study are that we have provided a
restricted gene expression profile for cultured cells at a
fixed time of stimulation. Concerning the first point, the
central weakness of microarray studies is that the signifi-
cance of individual levels of gene expression cannot easily
be addressed, nor is it possible to ascertain whether
mRNA levels accurately reflect polypeptide expression.
However, we feel that induced changes in gene expression
levels such as those observed here, and confirmed by
PCR, are likely to reflect changes in polypeptide product
levels irrespective of translational eﬃciency. Further, the
core gene set comprehensively covered the conventional
steroid biosynthetic pathway module, which was the main
purpose of the exercise. We duly acknowledge that
sensitivity of microarray may permit false-negative data,
i.e. apparent lack of expression of a gene, as compared
with metabolic profiling. However, as a site of major
endocrine-related gynaecological disease – including ovar-
ian cancer and endometriosis – there is an urgent need to
catalogue, characterise and comprehend the expression
profile of genes in HOSE cells involved in steroid signal-
ling, in order to define new diagnostic and therapeutic
targets. Regarding the second point, the only way that
suﬃcient HOSE cells for array analysis can be obtained
from individual patients is to biopsy and propagate in vitro,
as described here. The extent to which HOSE cells
propagated for 3 weeks in vitro reflect an in vivo phenotype
is diﬃcult to assess. However, a benefit of primary culture
is that any confounding patient-to-patient variable should
have been minimised, as suggested by the remarkably
uniform response to IL-1 given by the cells from all five
patients. A strength of this study is that it compared ‘like
with like’, that is, all samples were primary cell cultures,
and each had an untreated and a treated component,
identical to each other in all other ways. Selection of a
suitable control in gene profiling studies in HOSE has
recently been shown to dramatically eﬀect data and
interpretation (Zorn et al. 2003). Thirdly, the use of a 48 h
period of stimulation by fixed-dose IL-1 was a compro-
mise, based on previous evidence that 11HSD1 mRNA
and enzyme activity in HOSE cells are maximally stimu-
lated under these conditions. (Yong et al. 2002, Rae et al.
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2004). The trade-oﬀ for this restriction could be that
earlier gene changes might have been missed. These
criticisms aside, the dataset presented provides novel and
revealing information on this poorly understood specialised
human ovarian cell type.
In conclusion, we have used a custom oligonucleotide
microarray to define the steroidogenic potential of cul-
tured HOSE cells and investigate changes associated with
inflammatory stimulation through exposure to IL-1.
Results suggest that the HOSE is principally a site of
steroid metabolism and reception as opposed to de novo
steroid hormone synthesis. Intriguingly, the only ster-
oidogenic gene detectably up-regulated by IL-1 is
11HSD1. Non-steroidogenic genes aﬀected include
pro-/anti-inflammatory genes whose expression is
inhibited/augmented by corticosteroid. Since the ster-
oidogenic function of 11HSD1 is to regenerate cortisol
from cortisone, these results support the hypothesis
that locally produced glucocorticoids play significant
roles in HOSE cell function, including a possible
anti-inflammatory action around the time of ovulation.
Note added in proof
During preparation of this article for publication,
COUP-TF II has been found to be downregulated in
ovarian cancer cells (Lee et al. 2004).
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